Metoclopramide intranasal - Nasus Pharma
Alternative Names: NS-005Latest Information Update: 06 Mar 2024
At a glance
- Originator Nasus Pharma
- Class Aminobenzoic acids; Antiemetics; Antineoplastics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Phenyl ethers; Radiation-sensitising agents; Radiosensitisers; Small molecules
- Mechanism of Action Dopamine receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Nausea and vomiting
Most Recent Events
- 06 Mar 2024 NASUS Pharma has patent protection for NASAX technology (Nasus Pharma pipeline, March 2024).
- 09 Jan 2024 Early research in Nausea and vomiting in Israel (Intranasal) prior to January 2024 (Nasus Pharma pipeline, January 2024)